{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002709988,0.000286609,0.00133965,0.0002082659,0.00002051484,0.000009270268,0.0002733549,0.0001937033,0.0009609775],"category_scores_gemma":[0.00001375853,0.0001211273,0.0004157675,0.0003961801,0.0001363078,0.00001516205,0.00001839126,0.0001755761,0.000181515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001176393,"about_ca_system_score_gemma":0.001498315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008009699,"about_ca_topic_score_gemma":0.0000817705,"domain_scores_codex":[0.9982003,0.0001948761,0.0004685401,0.0003194583,0.000474715,0.0003420959],"domain_scores_gemma":[0.9988558,0.0002162451,0.0001409006,0.0006444168,0.00005677595,0.00008586198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002427761,0.0002928599,0.00006555648,0.00612644,0.0001238975,0.00004234898,0.0002972211,3.522457e-9,0.000001443212,0.00001872783,0.0027339,0.9902733],"study_design_scores_gemma":[0.00065193,0.0002782591,0.0002536422,0.01918188,0.0002885461,0.0001066575,0.00003434062,1.205675e-7,0.000005437065,0.000003411,0.9790844,0.0001113181],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004060407,0.9943005,4.127287e-7,0.0009333187,0.0001642857,0.00155378,0.0006801721,0.00001205815,0.002314832],"genre_scores_gemma":[0.00008853808,0.9966168,0.0000101897,0.00003887924,0.0005385281,0.0007628117,0.00002769195,0.00004010699,0.00187644],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.990162,"threshold_uncertainty_score":0.9999523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1386676677073322,"score_gpt":0.4761857603569551,"score_spread":0.337518092649623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}